|
KMID : 0370220230670040224
|
|
Yakhak Hoeji
2023 Volume.67 No. 4 p.224 ~ p.230
|
|
|
Analysis of Medical and Pharmaceutical Expenses for Lung Cancer Before and After the Introduction of Immunotherapy
|
|
Shin Da-Jeong
Park Mi-Hai
|
|
|
Abstract
|
|
|
|
Lung cancer has been the leading cause of cancer-related deaths in Korea and is considered one of the world’smost costly cancer to treat. Novel insights into the molecular biology of lung cancer discovered in recent years havefacilitated the use of targeted therapy and immunotherapy, arousing concerns over the financial burden of patients due tohigh healthcare costs. Using HIRA-NPS (Health Insurance Review & Assessment Service-National Patient Sample)database from 2015 to 2020, we analyzed lung cancer patients’ both medical and pharmaceutical expenditures. This studyfocused on targeted therapies and immunotherapies and compared these expenditures before and after the introduction ofimmunotherapy. In our analysis, the number of patients prescribed targeted drugs and immunotherapies for lung cancercontinues to increase yearly, and consequentially pharmaceutical expenses are also on the rise. An interrupted time seriesanalysis showed pharmaceutical expenditures for lung cancer increased immediately after the introduction of immunotherapyand have continued to increase since then, while total medical expenses, medical and pharmaceutical expenses per patienthave not shown any further increase after the immediate increase. The number of patients in immunotherapy has increasedbut there is little change in drug prices, such as drug price cuts or the entry of more expensive drugs, so the spendingper patient has not consistently increased.
|
|
|
KEYWORD
|
|
|
Lung cancer, Immunotherapy, Targeted therapy, Medical expenditures, Pharmaceutical expenditures
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|